Thursday, June 8Welcome

ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. complete business integration. ZyVersa plans to start trading on the Nasdaq on December 13, 2022 (ticker ‘ZVSA’)

ZyVersa is a clinical-stage biopharmaceutical company developing first-in-class product candidates for the treatment of kidney and inflammatory diseases.

weston, florida When bridgewater, new jersey, December 12, 2022 /PRNewswire/ — ZyVersa Therapeutics, Inc. (“ZyVersa”) is a clinical-stage focused biopharmaceutical company leveraging cutting-edge, proprietary technologies to treat kidney disease or inflammation with high unmet medical need. We develop products for patients with sexually transmitted diseases. Larkspur Health Acquisition Corp. (NASDAQ): LSPR or “Larkspur”), the special purpose acquisition company of Blank Check, is pleased to announce the completion of its previously announced business combination.

The business combination and related transactions were approved by Larkspur stockholders at a special meeting on March 12, 2018. December 8, 2022The combined company will operate as ZyVersa Therapeutics, Inc. under ZyVersa’s previous management team. Stephen C. GloverCo-Founder, CEO and Chairman of ZyVersa. Daniel J. O’ConnorFormer Chairman and Chief Executive Officer of Larkspur will join ZyVersa’s Board of Directors. ZyVersa common stock is expected to begin trading on the NASDAQ under the ticker symbol “ZVSA.” December 13, 2022Larkspur Warrants, previously traded under the symbol ‘LSPRW’, will no longer be listed for trading on the Nasdaq.

“Today marks an important milestone for ZyVersa. We are excited to complete our business integration with Larkspur and begin our next chapter as a public company,” said Glover. “We would like to thank our partners at Larkspur, our board of directors, and our colleagues at ZyVersa for their contributions to this achievement. We can take steps to advance IC 100, an inflammasome ASC inhibitor, to an investigational new drug application for patients with kidney disease,” continued Glover.

Mr O’Connor said: O’Connor continued, “We believe ZyVersa has the potential to build shareholder value based on the unique value proposition discussed in public filings.


The Benchmark Company LLC and Noble Capital Markets, Inc. are acting as financial advisors to ZyVersa, and Lowenstein Sandler LLP is acting as legal advisor to ZyVersa.

AGP/Alliance Global Partners, with Manatt, Phelps & Phillips, LLP serving as legal advisor, is acting as exclusive financial advisor to Larkspur. Alston & Bird LLP is acting as his Larkspur legal advisor.

About Larkspur Health Acquisition Corp.

Larkspur is a newly formed public company special purpose acquisition created to identify biopharmaceutical companies that can develop and thrive and benefit from Larkspur’s operational expertise and significant capital injection. Company (SPAC). Larkspur management and board members have joined former management and executive teams of private and/or public biopharmaceutical companies and collectively have more than 50 years of investment and operational experience. The team strongly believes in growth opportunities in the biotechnology industry. They are experienced operators looking to partner with top innovators and thinkers in the biopharmaceutical field. Their entrepreneurial approach supports management teams in making impactful decisions with an eye for growth and operational excellence. For more information, please visit

About Xyversa Therapeutics

ZyVersa is a clinical-stage specialty biopharmaceutical company that leverages advanced proprietary technologies to develop product candidates that address high unmet medical need in the areas of renal and inflammatory diseases. ZyVersa’s development pipeline includes his VAR 200 ready for Phase 2a. It is a cholesterol efflux mediator for the treatment of localized segmental glomerulosclerosis, a rare kidney disease. ZyVersa believes VAR 200 has the potential to treat other glomerular diseases, such as Alport syndrome and diabetic kidney disease. ZyVersa’s development pipeline also includes IC 100, a novel inflammasome ASC inhibitor being developed to treat a number of inflammatory diseases. For more information, please visit

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include descriptions. It relates to management’s intentions, plans, beliefs, expectations or projections of the future and, therefore, you are cautioned not to place undue reliance on them. Results may vary significantly from expectations. ZyVersa Therapeutics, Inc. (“ZyVersa”) “expects”, “believes”, “plans”, “expects”, “plans”, “future”, “intends”, “may” , and use words such as “to plan”. “may”, ”estimate”, “forecast”, “likely”, “continue”, “guidance” and similar expressions shall be subject to the Safe Harbor Clause. are intended to identify these forward-looking statements that are intended to be Such forward-looking statements are based on ZyVersa’s expectations and are subject to risks and uncertainties. As a result, actual results may be either expressed or implied in the statements due to a number of factors, including ZyVersa’s product candidate development and commercialization plans and the timing of the initiation of ZyVersa’s planned preclinical and clinical trials. can vary greatly. Timing of availability of data from preclinical and clinical studies of ZyVersa. the timing of any planned Investigational New Drug Applications or New Drug Applications; ZyVersa’s plans to research, develop and commercialize current and future product candidates; Clinical Utility, Potential Benefits, and Market Acceptance of ZyVersa Product Candidates. ZyVersa’s merchandising, marketing and manufacturing capabilities and strategies. Ability to Protect ZyVersa’s Intellectual Property Rights. ZyVersa’s estimates of future revenues, expenses, capital requirements and additional funding needs.

New factors arise from time to time, it is not possible for ZyVersa to predict all such factors, and ZyVersa cannot predict the impact each such factor will have on its business and the extent to which any factor or combination of factors will affect its business. cannot be evaluated. It could cause actual results to differ materially from those contained in the forward-looking statements. The forward-looking statements contained in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

This press release does not constitute an offer to sell or a solicitation of an offer to buy securities.

Source ZyVersa Therapeutics, Inc.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *